Dr. Reddys Laboratories Ltd (DRREDDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
122
About the Report
About the Report
Summary
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Dr. Reddy's Laboratories Ltd (DRREDDY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Dr. Reddy's Laboratories Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23
Private Equity 24
Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Partnerships 26
Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27
Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy's Labs 30
Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy's Labs 34
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy's Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39
Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Licensing Agreements 41
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Equity Offering 57
Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57
Asset Transactions 58
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60
Acquisition 61
Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61
Dr Reddy's Labs Acquires OctoPlus 62
Dr. Reddy's Laboratories Ltd-Key Competitors 64
Dr. Reddy's Laboratories Ltd-Key Employees 65
Dr. Reddy's Laboratories Ltd-Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Joint Venture 68
Recent Developments 69
Financial Announcements 69
Oct 26, 2018: Dr. Reddy's Q2 & H1 FY19 financial results 69
Jul 26, 2018: Dr. Reddy's Q1 FY19 financial results 70
May 22, 2018: Dr. Reddy's Q4 and FY18 Financial Results 72
Jan 25, 2018: Dr. Reddy's Q3 and 9M FY18 Financial Results 74
Oct 31, 2017: Dr. Reddy's Q2 and H1 FY18 Financial Results 76
Jul 27, 2017: Dr. Reddy's Q1 FY18 Financial Results 77
May 12, 2017: Dr. Reddy's Q4 and FY17 Financial Results 78
Feb 04, 2017: Dr. Reddy's Q3 and 9M FY17 Financial Results 80
Corporate Communications 82
Oct 25, 2018: Dr. Reddy's Laboratories: Appointment of Mr. Leo Puri as an Additional Director, categorjzed as Independent, on the Board of the Company 82
Jun 14, 2018: Dr. Reddy's Announces Resignation of Hans Peter Hasler As Independent Director 83
Mar 29, 2018: Dr. Reddy's Laboratories announces Senior Leadership Changes 84
Oct 30, 2017: Dr Reddys Laboratories appoints Prasad R Menon as an Additional Director 85
Legal and Regulatory 86
Oct 30, 2018: Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant 86
Aug 23, 2018: Dr. Reddy's Laboratories: Update on audit of API Srikakulam Plant, Andhra Pradesh 87
Jun 28, 2018: Dr. Reddy's Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1 88
Jun 28, 2018: Indivior's Temporary Restraining Order is Extended 89
Jun 03, 2018: Dr Reddy's API Srikakulam plant gets USFDA nod 90
Jun 02, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant 91
Apr 24, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Plant in Mirfield, UK 92
Mar 16, 2018: Dr. Reddy's Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana 93
Feb 25, 2018: Dr. Reddy's Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 94
Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit 95
Jan 24, 2018: Dr. Reddy's Laboratories: Intimation regard to Communication from Betapharm Arzneimittel, Germany from the Regulatory Authority of Germany 96
Jan 22, 2018: Dr. Reddy's fined USD 5mn by US court over drug packaging 97
Dec 19, 2017: Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the Consumer Product Safety Act 98
Dec 11, 2017: Dr. Reddys announced audit of formulations manufacturing plant 99
Dec 01, 2017: Dr. Reddy's Laboratories: Intimation regard to the US FDA audit 100
Nov 21, 2017: Dr. Reddy's Laboratories: Intimation regarding receipt of EIR 101
Sep 21, 2017: Dr. Reddys Announced audit of custom Pharmaceutical Services Facility 102
Sep 21, 2017: Dr. Reddy's Laboratories: Intimation about audit of Srikakulam Plant Unit II, Andhra Pradesh, by the US FDA 103
Sep 15, 2017: Dr. Reddy's Laboratories: Intimation about audit of API Mirfield Plant, United Kingdom, by the US FDA 104
Sep 08, 2017: Dr. Reddy's Laboratories: Regulatory Authority of Germany concludes audit of Formulations manufacturing facility in Vishakapatnam, India 105
Sep 08, 2017: Dr. Reddy's Laboratories Announces Intimation on audit 106
Jul 21, 2017: Dr. Reddy's Laboratories: Update On US FDA Audit at API Cuernavaca Plant 107
Jun 16, 2017: Dr. Reddy's Laboratories: Update on USFDA Audit 108
Jun 14, 2017: Dr. Reddy's Provides Update on API manufacturing plant at Miryalaguda 109
May 25, 2017: Dr. Reddy's Laboratories Provides Update on Srikakulum Plant 110
Apr 28, 2017: Dr. Reddy's Provides Update On US FDA Audit At Bachupally Plant 111
Apr 14, 2017: Dr. Reddy's Provides Update on USFDA Audit 112
Apr 03, 2017: Dr. Reddy's Laboratories Provides Update on USFDA Inspection at Srikakulam plant 113
Feb 21, 2017: Dr. Reddy's Laboratories Announces US FDA Inspection on Miryalaguda Facility 114
Product News 115
12/01/2017: Dr. Reddy's Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval 115
Aug 28, 2017: Dr. Reddy's Laboratories Breathes New Life into Doan's in New Marketing Campaign 116
Jun 03, 2018: Dr Reddy's expects to launch over 15 products in US in FY'19 117
Jan 17, 2018: Dr Reddy's recalls over 1,000 vials of cancer drug from US 118
Clinical Trials 119
Feb 07, 2018: Armis Biopharma to Present at the BIO CEO & Investor Conference 119
Jan 29, 2018: Armis Biopharma Granted QIDP for Lead Product, Ximycin for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery 120
Other Significant Developments 121
Feb 08, 2017: Dr. Reddy's Expands Commercial Operations in Europe 121
Appendix 122
Methodology 122
About GlobalData 122
Contact Us 122
Disclaimer 122
List of Figure
List of Figures
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23
Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27
Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy's Labs 30
Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy's Labs 34
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy's Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39
Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60
Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61
Dr Reddy's Labs Acquires OctoPlus 62
Dr. Reddy's Laboratories Ltd, Key Competitors 64
Dr. Reddy's Laboratories Ltd, Key Employees 65
Dr. Reddy's Laboratories Ltd, Subsidiaries 66
Dr. Reddy's Laboratories Ltd, Joint Venture 68
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.